Free Trial

Repligen (RGEN) Stock Price, News & Analysis

Repligen logo
$125.08 +3.68 (+3.03%)
As of 02:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Repligen Stock (NASDAQ:RGEN)

Key Stats

Today's Range
$120.36
$125.61
50-Day Range
$111.43
$134.00
52-Week Range
$102.96
$182.52
Volume
246,606 shs
Average Volume
780,328 shs
Market Capitalization
$7.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$169.45
Consensus Rating
Moderate Buy

Company Overview

Repligen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

RGEN MarketRank™: 

Repligen scored higher than 99% of companies evaluated by MarketBeat, and ranked 22nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Repligen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Repligen's stock forecast and price target.
  • Earnings Growth

    Earnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Repligen is -497.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Repligen is -497.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Repligen has a PEG Ratio of 2.06. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Repligen has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.40% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Repligen has recently decreased by 9.81%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Repligen does not currently pay a dividend.

  • Dividend Growth

    Repligen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.40% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Repligen has recently decreased by 9.81%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Repligen has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Repligen this week, compared to 10 articles on an average week.
  • Search Interest

    3 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Repligen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $201,834.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Repligen is held by insiders.

  • Percentage Held by Institutions

    97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Repligen's insider trading history.
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Repligen director Madaus buys $201k in shares
See More Headlines

RGEN Stock Analysis - Frequently Asked Questions

Repligen's stock was trading at $143.94 at the beginning of the year. Since then, RGEN stock has decreased by 13.5% and is now trading at $124.53.

Repligen Corporation (NASDAQ:RGEN) announced its quarterly earnings results on Tuesday, July, 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by $0.03. Repligen's quarterly revenue was up 14.8% on a year-over-year basis.
Read the conference call transcript
.

Repligen subsidiaries include these companies: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others.

Repligen's top institutional shareholders include Champlain Investment Partners LLC (2.49%), Geode Capital Management LLC (1.75%), Conestoga Capital Advisors LLC (1.74%) and Impax Asset Management Group plc (1.35%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax.
View institutional ownership trends
.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
7/29/2025
Today
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGEN
CIK
730272
Employees
1,778
Year Founded
1981

Price Target and Rating

High Price Target
$204.00
Low Price Target
$130.00
Potential Upside/Downside
+36.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
72.19
P/E Growth
2.06
Net Income
-$25.51 million
Net Margins
-2.05%
Pretax Margin
-2.02%
Return on Equity
4.61%
Return on Assets
3.24%

Debt

Debt-to-Equity Ratio
0.26
Current Ratio
8.59
Quick Ratio
7.32

Sales & Book Value

Annual Sales
$634.44 million
Price / Sales
11.01
Cash Flow
$3.45 per share
Price / Cash Flow
36.01
Book Value
$36.65 per share
Price / Book
3.39

Miscellaneous

Outstanding Shares
56,260,000
Free Float
55,583,000
Market Cap
$6.99 billion
Optionable
Optionable
Beta
1.05

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:RGEN) was last updated on 8/13/2025 by MarketBeat.com Staff
From Our Partners